Frequent structural variations involving programmed death ligands in Epstein-Barr virus-associated lymphomas

Keisuke Kataoka, Hiroaki Miyoshi, Seiji Sakata, Akito Dobashi, Lucile Couronné, Yasunori Kogure, Yasuharu Sato, Kenji Nishida, Yuka Gion, Yuichi Shiraishi, Hiroko Tanaka, Kenichi Chiba, Yosaku Watatani, Nobuyuki Kakiuchi, Yusuke Shiozawa, Tetsuichi Yoshizato, Kenichi Yoshida, Hideki Makishima, Masashi Sanada, Masahiro OnozawaTakanori Teshima, Yumiko Yoshiki, Tadao Ishida, Kenshi Suzuki, Kazuyuki Shimada, Akihiro Tomita, Motohiro Kato, Yasunori Ota, Koji Izutsu, Ayako Demachi-Okamura, Yoshiki Akatsuka, Satoru Miyano, Tadashi Yoshino, Philippe Gaulard, Olivier Hermine, Kengo Takeuchi, Koichi Ohshima, Seishi Ogawa

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Viral infection induces potent cellular immunity and activated intracellular signaling, which may dictate the driver events involved in immune escape and clonal selection of virus-associated cancers, including Epstein-Barr virus (EBV)-positive lymphomas. Here, we thoroughly interrogated PD-L1/PD-L2-involving somatic aberrations in 384 samples from various lymphoma subtypes using high-throughput sequencing, particularly focusing on virus-associated lymphomas. A high frequency of PD-L1/PD-L2-involving genetic aberrations was observed in EBV-positive lymphomas [33 (22%) of 148 cases], including extranodal NK/T-cell lymphoma (ENKTL, 23%), aggressive NK-cell leukemia (57%), systemic EBV-positive T-cell lymphoproliferative disorder (17%) as well as EBV-positive diffuse large B-cell lymphoma (DLBCL, 19%) and peripheral T-cell lymphoma-not otherwise specified (15%). Predominantly causing a truncation of the 3′-untranslated region, these alterations represented the most prevalent somatic lesions in ENKTL. By contrast, the frequency was much lower in EBV-negative lymphomas regardless of histology type [12 (5%) of 236 cases]. Besides PD-L1/PD-L2 alterations, EBV-positive DLBCL exhibited a genetic profile distinct from EBV-negative one, characterized by frequent TET2 and DNMT3A mutations and the paucity of CD79B, MYD88, CDKN2A, and FAS alterations. Our findings illustrate unique genetic features of EBV-associated lymphomas, also suggesting a potential role of detecting PD-L1/PD-L2-involving lesions for these lymphomas to be effectively targeted by immune checkpoint blockade.

Original languageEnglish
JournalLeukemia
DOIs
Publication statusAccepted/In press - Jan 1 2019

Fingerprint

Human Herpesvirus 4
Lymphoma
Ligands
Extranodal NK-T-Cell Lymphoma
Large Granular Lymphocytic Leukemia
Peripheral T-Cell Lymphoma
Viruses
Lymphoproliferative Disorders
Lymphoma, Large B-Cell, Diffuse
3' Untranslated Regions
Virus Diseases
Cellular Immunity
Histology
T-Lymphocytes
Mutation
Neoplasms

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Kataoka, K., Miyoshi, H., Sakata, S., Dobashi, A., Couronné, L., Kogure, Y., ... Ogawa, S. (Accepted/In press). Frequent structural variations involving programmed death ligands in Epstein-Barr virus-associated lymphomas. Leukemia. https://doi.org/10.1038/s41375-019-0380-5

Frequent structural variations involving programmed death ligands in Epstein-Barr virus-associated lymphomas. / Kataoka, Keisuke; Miyoshi, Hiroaki; Sakata, Seiji; Dobashi, Akito; Couronné, Lucile; Kogure, Yasunori; Sato, Yasuharu; Nishida, Kenji; Gion, Yuka; Shiraishi, Yuichi; Tanaka, Hiroko; Chiba, Kenichi; Watatani, Yosaku; Kakiuchi, Nobuyuki; Shiozawa, Yusuke; Yoshizato, Tetsuichi; Yoshida, Kenichi; Makishima, Hideki; Sanada, Masashi; Onozawa, Masahiro; Teshima, Takanori; Yoshiki, Yumiko; Ishida, Tadao; Suzuki, Kenshi; Shimada, Kazuyuki; Tomita, Akihiro; Kato, Motohiro; Ota, Yasunori; Izutsu, Koji; Demachi-Okamura, Ayako; Akatsuka, Yoshiki; Miyano, Satoru; Yoshino, Tadashi; Gaulard, Philippe; Hermine, Olivier; Takeuchi, Kengo; Ohshima, Koichi; Ogawa, Seishi.

In: Leukemia, 01.01.2019.

Research output: Contribution to journalArticle

Kataoka, K, Miyoshi, H, Sakata, S, Dobashi, A, Couronné, L, Kogure, Y, Sato, Y, Nishida, K, Gion, Y, Shiraishi, Y, Tanaka, H, Chiba, K, Watatani, Y, Kakiuchi, N, Shiozawa, Y, Yoshizato, T, Yoshida, K, Makishima, H, Sanada, M, Onozawa, M, Teshima, T, Yoshiki, Y, Ishida, T, Suzuki, K, Shimada, K, Tomita, A, Kato, M, Ota, Y, Izutsu, K, Demachi-Okamura, A, Akatsuka, Y, Miyano, S, Yoshino, T, Gaulard, P, Hermine, O, Takeuchi, K, Ohshima, K & Ogawa, S 2019, 'Frequent structural variations involving programmed death ligands in Epstein-Barr virus-associated lymphomas', Leukemia. https://doi.org/10.1038/s41375-019-0380-5
Kataoka, Keisuke ; Miyoshi, Hiroaki ; Sakata, Seiji ; Dobashi, Akito ; Couronné, Lucile ; Kogure, Yasunori ; Sato, Yasuharu ; Nishida, Kenji ; Gion, Yuka ; Shiraishi, Yuichi ; Tanaka, Hiroko ; Chiba, Kenichi ; Watatani, Yosaku ; Kakiuchi, Nobuyuki ; Shiozawa, Yusuke ; Yoshizato, Tetsuichi ; Yoshida, Kenichi ; Makishima, Hideki ; Sanada, Masashi ; Onozawa, Masahiro ; Teshima, Takanori ; Yoshiki, Yumiko ; Ishida, Tadao ; Suzuki, Kenshi ; Shimada, Kazuyuki ; Tomita, Akihiro ; Kato, Motohiro ; Ota, Yasunori ; Izutsu, Koji ; Demachi-Okamura, Ayako ; Akatsuka, Yoshiki ; Miyano, Satoru ; Yoshino, Tadashi ; Gaulard, Philippe ; Hermine, Olivier ; Takeuchi, Kengo ; Ohshima, Koichi ; Ogawa, Seishi. / Frequent structural variations involving programmed death ligands in Epstein-Barr virus-associated lymphomas. In: Leukemia. 2019.
@article{5b5f907ebdad4b59a0bd7f5bff83b0d5,
title = "Frequent structural variations involving programmed death ligands in Epstein-Barr virus-associated lymphomas",
abstract = "Viral infection induces potent cellular immunity and activated intracellular signaling, which may dictate the driver events involved in immune escape and clonal selection of virus-associated cancers, including Epstein-Barr virus (EBV)-positive lymphomas. Here, we thoroughly interrogated PD-L1/PD-L2-involving somatic aberrations in 384 samples from various lymphoma subtypes using high-throughput sequencing, particularly focusing on virus-associated lymphomas. A high frequency of PD-L1/PD-L2-involving genetic aberrations was observed in EBV-positive lymphomas [33 (22{\%}) of 148 cases], including extranodal NK/T-cell lymphoma (ENKTL, 23{\%}), aggressive NK-cell leukemia (57{\%}), systemic EBV-positive T-cell lymphoproliferative disorder (17{\%}) as well as EBV-positive diffuse large B-cell lymphoma (DLBCL, 19{\%}) and peripheral T-cell lymphoma-not otherwise specified (15{\%}). Predominantly causing a truncation of the 3′-untranslated region, these alterations represented the most prevalent somatic lesions in ENKTL. By contrast, the frequency was much lower in EBV-negative lymphomas regardless of histology type [12 (5{\%}) of 236 cases]. Besides PD-L1/PD-L2 alterations, EBV-positive DLBCL exhibited a genetic profile distinct from EBV-negative one, characterized by frequent TET2 and DNMT3A mutations and the paucity of CD79B, MYD88, CDKN2A, and FAS alterations. Our findings illustrate unique genetic features of EBV-associated lymphomas, also suggesting a potential role of detecting PD-L1/PD-L2-involving lesions for these lymphomas to be effectively targeted by immune checkpoint blockade.",
author = "Keisuke Kataoka and Hiroaki Miyoshi and Seiji Sakata and Akito Dobashi and Lucile Couronn{\'e} and Yasunori Kogure and Yasuharu Sato and Kenji Nishida and Yuka Gion and Yuichi Shiraishi and Hiroko Tanaka and Kenichi Chiba and Yosaku Watatani and Nobuyuki Kakiuchi and Yusuke Shiozawa and Tetsuichi Yoshizato and Kenichi Yoshida and Hideki Makishima and Masashi Sanada and Masahiro Onozawa and Takanori Teshima and Yumiko Yoshiki and Tadao Ishida and Kenshi Suzuki and Kazuyuki Shimada and Akihiro Tomita and Motohiro Kato and Yasunori Ota and Koji Izutsu and Ayako Demachi-Okamura and Yoshiki Akatsuka and Satoru Miyano and Tadashi Yoshino and Philippe Gaulard and Olivier Hermine and Kengo Takeuchi and Koichi Ohshima and Seishi Ogawa",
year = "2019",
month = "1",
day = "1",
doi = "10.1038/s41375-019-0380-5",
language = "English",
journal = "Leukemia",
issn = "0887-6924",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Frequent structural variations involving programmed death ligands in Epstein-Barr virus-associated lymphomas

AU - Kataoka, Keisuke

AU - Miyoshi, Hiroaki

AU - Sakata, Seiji

AU - Dobashi, Akito

AU - Couronné, Lucile

AU - Kogure, Yasunori

AU - Sato, Yasuharu

AU - Nishida, Kenji

AU - Gion, Yuka

AU - Shiraishi, Yuichi

AU - Tanaka, Hiroko

AU - Chiba, Kenichi

AU - Watatani, Yosaku

AU - Kakiuchi, Nobuyuki

AU - Shiozawa, Yusuke

AU - Yoshizato, Tetsuichi

AU - Yoshida, Kenichi

AU - Makishima, Hideki

AU - Sanada, Masashi

AU - Onozawa, Masahiro

AU - Teshima, Takanori

AU - Yoshiki, Yumiko

AU - Ishida, Tadao

AU - Suzuki, Kenshi

AU - Shimada, Kazuyuki

AU - Tomita, Akihiro

AU - Kato, Motohiro

AU - Ota, Yasunori

AU - Izutsu, Koji

AU - Demachi-Okamura, Ayako

AU - Akatsuka, Yoshiki

AU - Miyano, Satoru

AU - Yoshino, Tadashi

AU - Gaulard, Philippe

AU - Hermine, Olivier

AU - Takeuchi, Kengo

AU - Ohshima, Koichi

AU - Ogawa, Seishi

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Viral infection induces potent cellular immunity and activated intracellular signaling, which may dictate the driver events involved in immune escape and clonal selection of virus-associated cancers, including Epstein-Barr virus (EBV)-positive lymphomas. Here, we thoroughly interrogated PD-L1/PD-L2-involving somatic aberrations in 384 samples from various lymphoma subtypes using high-throughput sequencing, particularly focusing on virus-associated lymphomas. A high frequency of PD-L1/PD-L2-involving genetic aberrations was observed in EBV-positive lymphomas [33 (22%) of 148 cases], including extranodal NK/T-cell lymphoma (ENKTL, 23%), aggressive NK-cell leukemia (57%), systemic EBV-positive T-cell lymphoproliferative disorder (17%) as well as EBV-positive diffuse large B-cell lymphoma (DLBCL, 19%) and peripheral T-cell lymphoma-not otherwise specified (15%). Predominantly causing a truncation of the 3′-untranslated region, these alterations represented the most prevalent somatic lesions in ENKTL. By contrast, the frequency was much lower in EBV-negative lymphomas regardless of histology type [12 (5%) of 236 cases]. Besides PD-L1/PD-L2 alterations, EBV-positive DLBCL exhibited a genetic profile distinct from EBV-negative one, characterized by frequent TET2 and DNMT3A mutations and the paucity of CD79B, MYD88, CDKN2A, and FAS alterations. Our findings illustrate unique genetic features of EBV-associated lymphomas, also suggesting a potential role of detecting PD-L1/PD-L2-involving lesions for these lymphomas to be effectively targeted by immune checkpoint blockade.

AB - Viral infection induces potent cellular immunity and activated intracellular signaling, which may dictate the driver events involved in immune escape and clonal selection of virus-associated cancers, including Epstein-Barr virus (EBV)-positive lymphomas. Here, we thoroughly interrogated PD-L1/PD-L2-involving somatic aberrations in 384 samples from various lymphoma subtypes using high-throughput sequencing, particularly focusing on virus-associated lymphomas. A high frequency of PD-L1/PD-L2-involving genetic aberrations was observed in EBV-positive lymphomas [33 (22%) of 148 cases], including extranodal NK/T-cell lymphoma (ENKTL, 23%), aggressive NK-cell leukemia (57%), systemic EBV-positive T-cell lymphoproliferative disorder (17%) as well as EBV-positive diffuse large B-cell lymphoma (DLBCL, 19%) and peripheral T-cell lymphoma-not otherwise specified (15%). Predominantly causing a truncation of the 3′-untranslated region, these alterations represented the most prevalent somatic lesions in ENKTL. By contrast, the frequency was much lower in EBV-negative lymphomas regardless of histology type [12 (5%) of 236 cases]. Besides PD-L1/PD-L2 alterations, EBV-positive DLBCL exhibited a genetic profile distinct from EBV-negative one, characterized by frequent TET2 and DNMT3A mutations and the paucity of CD79B, MYD88, CDKN2A, and FAS alterations. Our findings illustrate unique genetic features of EBV-associated lymphomas, also suggesting a potential role of detecting PD-L1/PD-L2-involving lesions for these lymphomas to be effectively targeted by immune checkpoint blockade.

UR - http://www.scopus.com/inward/record.url?scp=85060671911&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85060671911&partnerID=8YFLogxK

U2 - 10.1038/s41375-019-0380-5

DO - 10.1038/s41375-019-0380-5

M3 - Article

C2 - 30683910

AN - SCOPUS:85060671911

JO - Leukemia

JF - Leukemia

SN - 0887-6924

ER -